A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Prior treatment

• Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
• Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
• Have had within 90 days prior to screening:
  • heart attack
  • stroke
  • coronary artery revascularization
  • unstable angina, or
  • hospitalization due to congestive heart failure
• Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Other illness

• Have type 1 diabetes
• Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

Lab values

• Have taken any of the following antihyperglycemic medications within 90 days before screening:
  • amylin analogs
  • glucagon-like peptide-1 (GLP-1) receptor agonists
  • glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or
  • insulin

• Have type 2 diabetes
• Are on stable treatment for type 2 diabetes for at least 90 days prior to screening
• Have a BMI ≥ 27 kg/m2
• Have a stable body weight (\<5% body weight change) for 90 days prior to screening